Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study

被引：0
|
作者：
Smolen, Josef S. [1 ,2 ]
van Vollenhoven, Ronald [3 ]
Kavanaugh, Arthur [4 ]
Strand, Vibeke [5 ]
Vencovsky, Jiri [6 ]
Schiff, Michael H. [7 ]
Landewe, Robert [8 ,9 ]
Haraoui, Boulos [10 ]
Walker, Susan [11 ]
van der Heijde, Desiree [12 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Hietzing Hosp, Vienna, Austria
[3] Karolinska Inst, Stockholm, Sweden
[4] Univ Calif San Diego, San Diego, CA 92103 USA
[5] Stanford Univ, Palo Alto, CA 94304 USA
[6] Charles Univ Prague, Dept Clin & Expt Rheumatol, Inst Rheumatol, Fac Med 1, Prague, Czech Republic
[7] Univ Colorado, Denver, CO 80202 USA
[8] Acad Med Ctr Amsterdam, Heerlen, Netherlands
[9] Atrium Med Ctr, Heerlen, Netherlands
[10] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[11] UCB Pharma, Raleigh, NC USA
[12] Leiden Univ, Med Ctr, Leiden, Netherlands
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2321
引用
收藏
页码：S988 / S989
页数：2
相关论文
共 50 条
  • [1] Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 24-Week Randomized Controlled Trial and Open-Label Extension Study
    Smolen, Josef
    Van Vollenhoven, Ronald
    Kavanaugh, Arthur
    Strand, Vibeke
    Vencovsky, Jiri
    Schiff, Michael
    Landewe, Robert
    Haraoui, Boulos
    Walker, Susan
    van der Heijde, Desiree
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1506 - 1507
  • [2] Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Philip J.
    Shaughnessy, Laura
    VanLunen, Brenda
    van der Heijde, Desiree
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S596 - S597
  • [3] LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: 5-YEAR RESULTS FROM A 52-WEEK RANDOMIZED CONTROLLED TRIAL AND OPEN-LABEL EXTENSION STUDY
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Philip J.
    Shaughnessy, Laura
    vanlunen, Brenda
    van der Heijde, Desiree
    RHEUMATOLOGY, 2014, 53 : 96 - 96
  • [4] Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Phillip
    Shaughnessy, Laura
    VanLunen, Brenda
    van der Heijde, Desiree
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1455 - 1456
  • [5] 5-YEAR RESULTS FROM THE RAPID 1 TRIAL AND OPEN-LABEL EXTENSION: LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
    Keystone, E.
    Landewe, R.
    van Vollenhoven, R.
    Combe, B.
    Strand, V.
    Mease, P. J.
    Shaughnessy, L.
    VanLunen, B.
    van der Heijde, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 228 - 229
  • [6] Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Philip
    Shaughnessy, Laura
    VanLunen, Brenda
    van der Heijde, Desiree
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (12) : 2094 - 2100
  • [7] LONG-TERM SAFETY AND EFFICACY OF 4-WEEKLY CERTOLIZUMAB PEGOL MONOTHERAPY AND COMBINATION THERAPY IN RHEUMATOID ARTHRITIS: 5-YEAR RESULTS FROM AN OPEN-LABEL EXTENSION STUDY
    Fleischmann, R.
    van Vollenhoven, R.
    Vencovsky, J.
    Alten, R.
    Davies, O.
    Stach, C.
    de Longueville, M.
    VanLunen, B.
    Choy, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 435 - 435
  • [8] Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
    Fleischmann, Roy M.
    van Vollenhoven, Ronald F.
    Vencovsky, Jiri
    Alten, Rieke
    Davies, Owen
    Stach, Christian
    de Longueville, Marc
    Van Lunen, Brenda
    Choy, Ernest
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S565 - S566
  • [9] LONG-TERM SAFETY OF 4-WEEKLY CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS: 5 YEAR RESULTS FROM AN OPEN LABEL EXTENSION STUDY
    Fleischmann, R.
    van Vollenhoven, R.
    Vencovsky, J.
    Alten, R.
    Davies, O.
    Stach, C.
    de Longueville, M.
    van Lunen, B.
    Choy, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 523 - 523
  • [10] Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study
    Tanaka, Yoshiya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Eguchi, Katsumi
    Watanabe, Akira
    Origasa, Hideki
    Shoji, Toshiharu
    Miyasaka, Nobuyuki
    Koike, Takao
    MODERN RHEUMATOLOGY, 2014, 24 (05) : 725 - 733
12345